Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05963698 · ClinicalTrials.gov registry record · NA

The Fourth Left Atrial Appendage Occlusion Study

A NA study of Atrial Fibrillation and Stroke, Ischemic, sponsored by Hamilton Health Sciences Corporation.

Recruiting
Registry status
NA
Development phase
4,000
Enrollment target
20
Study locations

NCT05963698 is a NA study of Atrial Fibrillation and Stroke, Ischemic that is actively recruiting participants, run by Hamilton Health Sciences Corporation. The registered enrollment target is 4,000 participants, above the 2,977-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05963698, a NA study of Atrial Fibrillation and Stroke, Ischemic, is actively recruiting participants, sponsored by Hamilton Health Sciences Corporation.

RECRUITING
Registry status
NA
Development phase
4,000 participants
Enrollment target
20
Study locations

Study Summary

LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

Conditions Studied

Atrial Fibrillation Stroke, Ischemic Systemic Embolism

Interventions

  • DEVICE WATCHMAN device

Study Locations (20)

California

  • Memorial Health Services - Fountain Valley
  • Loma Linda University Health - Loma Linda
  • Southern California Permanente Medical Group - Pasadena
  • Sutter Valley Hospitals dba Sutter Institute for Medical Research - Sacramento

Florida

  • JFK Medical Center Limited Partnership d/b/a HCA Florida JFK Hospital - Atlantis
  • St. Vincent's Health System - Jacksonville
  • Largo Medical Center, Inc. d/b/a HCA Florida Largo Medical Center - Largo
  • The University of South Florida - Tampa

Idaho

  • St Luke's Regional Medical Center, Ltd - Boise
  • Kootenai Health Inc. - Coeur d'Alene

Illinois

  • Northwestern University - Evanston
  • Cardiovascular Medicine, PLLC and Unity Point Trinity Rock Island - Rock Island

Alabama

  • Affinity Hospital dba Grandview Medical Center - Birmingham

Arkansas

  • Arrhythmia Research Group - Jonesboro

Georgia

  • Emory University - Atlanta

Indiana

  • Community Health Network Inc. - Indianapolis

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2023-11-30
Est. Completion 2029-12-01
Phase NA

Sponsor

Hamilton Health Sciences Corporation

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05963698

The ClinicalTrials.gov registry entry for NCT05963698 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,977-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (34% higher). The listed sponsor is Hamilton Health Sciences Corporation, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which WATCHMAN device is the first listed.

NCT05963698 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Idaho.

Frequently Asked Questions

What is clinical trial NCT05963698 about?

NCT05963698 is a clinical study titled "The Fourth Left Atrial Appendage Occlusion Study". LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

What is the current status of trial NCT05963698?

This trial is currently recruiting. It is a NA study. The enrollment target is 4,000 participants. The study started on 2023-11-30. Estimated completion is 2029-12-01.

What conditions does trial NCT05963698 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism.

What interventions are being tested in trial NCT05963698?

The interventions under investigation include: WATCHMAN device (DEVICE).

Who is sponsoring clinical trial NCT05963698?

This trial is sponsored by Hamilton Health Sciences Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05963698 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Stroke, Ischemic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.